Non-small cell lung carcinoma, Cancer, Lung cancer
BNTXBioNTech SECatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for BNT316 (ONC-392) in Non-small cell lung carcinoma, Cancer, Lung cancer. The expected timing is based on the latest available company guidance and may change.
Collaboration w/ OncoC4. Positive Ph1/2 data from an expansion cohort at ASCO 2023 and in SITC 2023. 6/29/23- Initiated Ph3. Preliminary Phase 2 data at ESMO '24 on 9/15. 03/24/26:- Stage 1 Ph3 PRESERVE-003 showed OS benefit in 2L+ sqNSCLC; ELCC March 27, 2026. Pivotal stage ongoing. 08/20/26:- Updated PRESERVE-003 stage 1 OS to present at WCLC Sep 14, 2026.
Verification
Confirm timing and program details against the company announcement or filing.